EyeGene Full Year 2023 Earnings 975 loss per share - Simply Wall St
| 185490 Stock | KRW 2,805 20.00 0.71% |
About 62% of EyeGene's investor base is looking to short. The analysis of current outlook of investing in EyeGene suggests that many traders are alarmed regarding EyeGene's prospects. The current market sentiment, together with EyeGene's historical and current headlines, can help investors time the market. In addition, many technical investors use EyeGene stock news signals to limit their universe of possible portfolio assets.
EyeGene |
EyeGene Full Year 2023 Earnings 975 loss per share Simply Wall St
Read at news.google.com
 |
EyeGene Fundamental Analysis
We analyze EyeGene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EyeGene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EyeGene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Market Capitalization
Market Capitalization Comparative Analysis
EyeGene is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
EyeGene Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with EyeGene stock to make a market-neutral strategy. Peer analysis of EyeGene could also be used in its relative valuation, which is a method of valuing EyeGene by comparing valuation metrics with similar companies.
Peers
EyeGene Related Equities
| 026890 | Digital Power | 4.11 | ||||
| 025770 | Korea Information | 0.12 | ||||
| 051910 | LG Chemicals | 0.53 | ||||
| 020180 | Daishin Information | 1.40 | ||||
| 036630 | Sejong Telecom | 2.27 | ||||
| 286940 | Lotte Data | 3.02 |
Complementary Tools for EyeGene Stock analysis
When running EyeGene's price analysis, check to measure EyeGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EyeGene is operating at the current time. Most of EyeGene's value examination focuses on studying past and present price action to predict the probability of EyeGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EyeGene's price. Additionally, you may evaluate how the addition of EyeGene to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |